Back to News
Market Impact: 0.1
Seraxis Names Former FDA Medical Officer Patricia Beaston As Chief Medical Officer Ahead Of Merger
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Seraxis Holdings and Sernova Biotherapeutics announced Patricia Beaston's appointment as Chief Medical Officer of Seraxis. The brief announcement provides no further details on her background or the expected impact of the appointment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Netflix film boss Dan Lin out as streaming giant continues to overhaul top ranks
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals
- What Makes Financial Data Ready for AI Research?